Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among Physicians

Documenti analoghi

• Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European Countries
  di: Sandrine Colas, et al.
  Pubblicazione: (2024)
• Effectiveness of Baricitinib Risk Minimization Activities in Patients With Rheumatoid Arthritis—A Cohort Study in Four Nordic Countries
  di: Mikkel Z. Ankarfeldt, et al.
  Pubblicazione: (2024)
• Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review
  di: Xabier Aizpurua‐Arruti, et al.
  Pubblicazione: (2025)
• Current Use of Common Data Models in the Nordic Countries
  di: Gerard Ompad, et al.
  Pubblicazione: (2025)
• Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees
  di: Leila Karimi, et al.
  Pubblicazione: (2026)